 SYDNEY , April 29, 2022 PRNewswire -- Kazia Therapeutics Limited NASDAQ: KZIA; ASX: KZA, an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology ASCO. The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022 and will be held in Chicago, IL. 